Day: October 27, 2026

Purespring Therapeutics advances kidney-targeted gene therapy PS-003 towards the clinic in X-linked Alport Syndrome, with new preclinical and epidemiological data presented at ASN Kidney Week 2026

PS-003 is designed to address the underlying genetic cause of X-linked Alport Syndrome (XLAS), and new preclinical data demonstrate the restoration...

error: Content is protected !!